Antihypertensive effects of CBD are mediated by altered inflammatory response: A sub-study of the HYPER-H21-4 trial
Despite the abundance of preclinical data, cardiovascular effects of cannabidiol (CBD) in humans remain controversial. HYPER-H21-4 trial was designed as a randomized, placebo-controlled, crossover trial aimed to explore the effects of chronic CBD dosing on ambulatory blood pressure (BP) and vascular...
Main Authors: | Hrvoje Urlic, Marko Kumric, Goran Dujic, Josip Vrdoljak, Daniela Supe-Domic, Zeljko Dujic, Josko Bozic |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-11-01
|
Series: | Journal of Functional Foods |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1756464623004735 |
Similar Items
-
CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial
by: Marko Kumric, et al.
Published: (2023-04-01) -
Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension: A sub-analysis of the HYPER-H21-4 trial
by: Marko Kumric, et al.
Published: (2023-08-01) -
Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study
by: Marko Kumric, et al.
Published: (2022-06-01) -
Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study
by: Ana Batinic, et al.
Published: (2023-06-01) -
Serum Catestatin Levels Correlate with Ambulatory Blood Pressure and Indices of Arterial Stiffness in Patients with Primary Hypertension
by: Marko Kumric, et al.
Published: (2022-08-01)